- Home
- ACCL vs SCLX Comparison
ACCL vs SCLX Comparison
Compare ACCL & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCL
- SCLX
- Stock Information
- Founded
- ACCL 2009
- SCLX 2011
- Country
- ACCL Hong Kong
- SCLX United States
- Employees
- ACCL N/A
- SCLX N/A
- Industry
- ACCL Professional Services
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ACCL Consumer Discretionary
- SCLX Health Care
- Exchange
- ACCL Nasdaq
- SCLX Nasdaq
- Market Cap
- ACCL 32.1M
- SCLX 35.7M
- IPO Year
- ACCL 2025
- SCLX N/A
- Fundamental
- Price
- ACCL $2.96
- SCLX $18.44
- Analyst Decision
- ACCL
- SCLX Buy
- Analyst Count
- ACCL 0
- SCLX 2
- Target Price
- ACCL N/A
- SCLX $245.00
- AVG Volume (30 Days)
- ACCL 440.5K
- SCLX 240.2K
- Earning Date
- ACCL 11-20-2025
- SCLX 08-13-2025
- Dividend Yield
- ACCL N/A
- SCLX N/A
- EPS Growth
- ACCL N/A
- SCLX N/A
- EPS
- ACCL 0.09
- SCLX N/A
- Revenue
- ACCL $4,874,058.00
- SCLX $44,236,000.00
- Revenue This Year
- ACCL N/A
- SCLX $89.26
- Revenue Next Year
- ACCL N/A
- SCLX $203.95
- P/E Ratio
- ACCL $33.28
- SCLX N/A
- Revenue Growth
- ACCL 17.95
- SCLX N/A
- 52 Week Low
- ACCL $2.10
- SCLX $3.60
- 52 Week High
- ACCL $4.45
- SCLX $39.90
- Technical
- Relative Strength Index (RSI)
- ACCL N/A
- SCLX 53.25
- Support Level
- ACCL N/A
- SCLX $13.08
- Resistance Level
- ACCL N/A
- SCLX $20.02
- Average True Range (ATR)
- ACCL 0.00
- SCLX 1.56
- MACD
- ACCL 0.00
- SCLX 0.56
- Stochastic Oscillator
- ACCL 0.00
- SCLX 78.65
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.